Oxford Genome Sciences appoints Jeff Warren
Oxford Genome Sciences (UK) Ltd (OGeS) announced the appointment of Jeff Warren as its first non-executive director. Mr Warren brings nearly 30 years financial management experience, including high level corporate governance and regulatory environment experience, having served as a Finance Director and CEO in the UK Financial services industry.
Jeff Warren was CFO of Bristol and West Building Society from 1992. Following the acquisition of Bristol and West by Bank of Ireland, he was appointed CEO of Bristol and West PLC in 1999, and subsequently also given responsibility for the Bank of Ireland UK Branch network. In 2003 he moved to take on a role at Group level in Dublin, as Group Chief Development Officer, reporting to the Bank of Ireland CEO. In 2004 he returned to the UK to develop a career as a non-executive director.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Innovative Roche cancer medicine Avastin approved in EU - First Treatment of its Kind With Proven Survival Benefit for Patients With Advanced Colorectal Cancer
VASTox gaint Duchenne Muscular Dystrophy patent
East German physicians prescribe significantly more high-priced biopharmaceutical medication than West German doctors - 127% higher revenues of pharmaceutical companies per physician and year in the area of former East Germany
Apeiron announces start of phase I trail with cellular anti cancer therapy
Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility
Acacia Pharma starts clinical trial with APD515 for Xerostomia

Innovative therapeutic tools in the fight against cancer - Spin-off company of the University Medical Center Mainz starts operations and enters into joint venture with Indivumed
Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development
Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
